Loading...
Loading...
ERAS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.9M |
| Gross Profit | -0.9M |
| Operating Expense | 34.7M |
| Operating I/L | -34.7M |
| Other Income/Expense | 4.3M |
| Interest Income | 4.3M |
| Pretax | -30.4M |
| Income Tax Expense | -5.3M |
| Net Income/Loss | -30.4M |
Erasca, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ERAS-601, an oral SHP2 inhibitor for advanced or metastatic solid tumors; and ERAS-801, a central nervous system-penetrant EGFR inhibitor for recurrent glioblastoma multiforme.
